FLHLF News and Press, Filament Health From 05/19/25

FILAMENT HEALTH ANNOUNCES VOLUNTARY DELISTING FROM CBOE CANADA Canada NewsWire VANCOUVER, BC , May 19, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) (" Filament " or the " Company "), a clinical‐stage natural psyc...

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , May 8, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage na...

FILAMENT HEALTH ANNOUNCES FDA AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING PEX010, THE COMPANY'S BOTANICAL PSILOCYBIN DRUG CANDIDATE, IN OPIOID USE DISORDER Canada NewsWire The University of Pennsylvania -sponsored trial will study PEX010 for the treatment of opioid us...

2025-04-04 05:35:26 ET More on Filament Health Financial information for Filament Health Read the full article on Seeking Alpha For further details see: Filament Health to raise C$0.9M, delist from Cboe Canada

FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT AND INTENTION TO VOLUNTARILY DELIST FROM CBOE CANADA Canada NewsWire Financing driven by existing investor Negev and Filament's Board of Directors Company also announces intention to voluntarily delist from Cboe Canada ...

FILAMENT HEALTH ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF PEX010 IN PATIENTS WITH ALCOHOL USE DISORDER Canada NewsWire Open-label study at Psychiatric Centre Copenhagen found that alcohol consumption significantly decreased amongst participants dosed with Filament's botani...

FILAMENT HEALTH ANNOUNCES SHIPMENT OF BOTANICAL PSILOCYBIN TO THE UNIVERSITY OF WISCONSIN-MADISON Canada NewsWire UW-Madison, a globally recognized psychiatric research institution, will study Filament's botanical psilocybin drug candidate, PEX010, in two clinical trials explo...